Victory Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-19,817
| Closed | -$797K | – | 2488 |
|
|
2026
Q1 | $797K | Buy |
19,817
+4,620
| +30% | +$99.6K | ﹤0.01% | 1922 |
|
|
2025
Q4 | $382K | Sell |
15,197
-75
| -0.5% | -$1.76K | ﹤0.01% | 2081 |
|
|
2025
Q3 | $346K | Sell |
15,272
-303
| -2% | -$7.07K | ﹤0.01% | 2120 |
|
|
2025
Q2 | $270K | Sell |
15,575
-199,577
| -93% | -$3.69M | ﹤0.01% | 2181 |
|
|
2025
Q1 | $4.71M | Sell |
215,152
-347,117
| -62% | -$9.59M | ﹤0.01% | 1300 |
|
|
2024
Q4 | $17.9M | Buy |
562,269
+150,363
| +37% | +$4.52M | 0.02% | 889 |
|
|
2024
Q3 | $11.9M | Sell |
411,906
-49,960
| -11% | -$1.85M | 0.01% | 1045 |
|
|
2024
Q2 | $17.7M | Sell |
461,866
-30,031
| -6% | -$1.36M | 0.02% | 850 |
|
|
2024
Q1 | $28.9M | Sell |
491,897
-124,375
| -20% | -$7.93M | 0.03% | 682 |
|
|
2023
Q4 | $36.9M | Sell |
616,272
-122,239
| -17% | -$6.2M | 0.04% | 544 |
|
|
2023
Q3 | $28.1M | Buy |
738,511
+337,554
| +84% | +$14.8M | 0.03% | 624 |
|
|
2023
Q2 | $36.5M | Sell |
400,957
-161,212
| -29% | -$13.9M | 0.04% | 535 |
|
|
2023
Q1 | $37.1M | Buy |
562,169
+131,618
| +31% | +$7.59M | 0.04% | 543 |
|
|
2022
Q4 | $22.3M | Sell |
430,551
-242,500
| -36% | -$12.9M | 0.03% | 737 |
|
|
2022
Q3 | $46M | Sell |
673,051
-25,120
| -4% | -$1.49M | 0.05% | 488 |
|
|
2022
Q2 | $31.6M | Sell |
698,171
-626,793
| -47% | -$28.6M | 0.04% | 643 |
|
|
2022
Q1 | $67.2M | Sell |
1,324,964
-241,013
| -15% | -$10.6M | 0.07% | 406 |
|
|
2021
Q4 | $74M | Sell |
1,565,977
-204,830
| -12% | -$8.06M | 0.07% | 395 |
|
|
2021
Q3 | $58.4M | Buy |
1,770,807
+114,519
| +7% | +$6.43M | 0.06% | 481 |
|
|
2021
Q2 | $105M | Sell |
1,656,288
-277,492
| -14% | -$14.3M | 0.1% | 254 |
|
|
2021
Q1 | $83M | Buy |
1,933,780
+23,803
| +1% | +$1.13M | 0.09% | 332 |
|
|
2020
Q4 | $109M | Sell |
1,909,977
-235,485
| -11% | -$9.96M | 0.12% | 227 |
|
|
2020
Q3 | $64.7M | Buy |
2,145,462
+180,917
| +9% | +$5.41M | 0.08% | 350 |
|
|
2020
Q2 | $64.2M | Sell |
1,964,545
-1,768,285
| -47% | -$56.8M | 0.09% | 338 |
|
|
2020
Q1 | $100M | Buy |
3,732,830
+1,563,481
| +72% | +$55.5M | 0.08% | 337 |
|
|
2019
Q4 | $66.4M | Buy |
2,169,349
+367,907
| +20% | +$10.2M | 0.08% | 369 |
|
|
2019
Q3 | $43.4M | Buy |
1,801,442
+139,239
| +8% | +$3.83M | 0.06% | 504 |
|
|
2019
Q2 | $42.1M | Sell |
1,662,203
-26,460
| -2% | -$538K | 0.09% | 367 |
|
|
2019
Q1 | $32.9M | Buy |
1,688,663
+300,900
| +22% | +$4.73M | 0.07% | 413 |
|
|
2018
Q4 | $18.3M | Buy |
1,387,763
+40,010
| +3% | +$614K | 0.05% | 571 |
|
|
2018
Q3 | $24M | Buy |
1,347,753
+415,000
| +44% | +$7.67M | 0.05% | 559 |
|
|
2018
Q2 | $20.5M | Buy |
932,753
+559,913
| +150% | +$12.9M | 0.04% | 592 |
|
|
2018
Q1 | $8.24M | Buy |
+372,840
| New | +$7.33M | 0.02% | 775 |
|
Other funds holding APLS
Victory Capital Management's APLS Position: Q2 2026 in Review
Victory Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 19,817 shares — an estimated $797K sold.
Victory Capital Management first reported a position in APLS in Q1 2018 and held it in 33 quarters. The position peaked at $109M in Q4 2020. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Victory Capital Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Victory Capital Management sold 19,817 Apellis Pharmaceuticals shares in Q2 2026, an estimated $797K.
- Victory Capital Management first reported a position in Apellis Pharmaceuticals in Q1 2018 and held it in 33 quarters.
- Victory Capital Management's Apellis Pharmaceuticals position peaked at $109M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.